Humana (NYSE:HUM) Price Target Increased to $570.00 by Analysts at Barclays

Humana (NYSE:HUMGet Rating) had its price objective boosted by Barclays from $500.00 to $570.00 in a research note issued to investors on Thursday morning, The Fly reports. Barclays currently has a maintains rating on the insurance provider’s stock.

Several other equities analysts have also recently weighed in on HUM. Mizuho lifted their price target on Humana from $500.00 to $529.00 and gave the company a maintains rating in a research report on Thursday. Truist Financial lifted their price target on Humana from $490.00 to $550.00 and gave the company a hold rating in a research report on Thursday, July 14th. Sanford C. Bernstein assumed coverage on Humana in a research report on Thursday, May 26th. They issued a market perform rating and a $506.00 price target for the company. Credit Suisse Group set a $548.00 price target on Humana in a research report on Tuesday, July 19th. Finally, Oppenheimer lifted their price target on Humana from $510.00 to $520.00 and gave the company an outperform rating in a research report on Thursday. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $511.44.

Humana Stock Performance

NYSE:HUM opened at $482.00 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.53. The business has a fifty day simple moving average of $462.13 and a two-hundred day simple moving average of $440.76. Humana has a 1 year low of $351.20 and a 1 year high of $497.47. The company has a market capitalization of $60.97 billion, a P/E ratio of 20.45, a P/E/G ratio of 1.42 and a beta of 0.80.

Humana (NYSE:HUMGet Rating) last released its earnings results on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.67 by $1.00. Humana had a return on equity of 17.27% and a net margin of 3.51%. The business had revenue of $23.66 billion during the quarter, compared to the consensus estimate of $23.44 billion. During the same period last year, the business posted $6.89 earnings per share. The business’s revenue for the quarter was up 14.6% on a year-over-year basis. On average, analysts expect that Humana will post 24.65 earnings per share for the current year.

Insider Activity

In other news, insider Samir Deshpande sold 3,957 shares of the business’s stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $434.19, for a total value of $1,718,089.83. Following the completion of the sale, the insider now owns 5,529 shares of the company’s stock, valued at approximately $2,400,636.51. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.39% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Humana

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in Humana by 4.4% during the 1st quarter. BlackRock Inc. now owns 11,751,892 shares of the insurance provider’s stock valued at $5,114,071,000 after purchasing an additional 497,536 shares during the last quarter. Vanguard Group Inc. raised its position in Humana by 9.2% during the 1st quarter. Vanguard Group Inc. now owns 10,927,647 shares of the insurance provider’s stock valued at $4,755,384,000 after purchasing an additional 919,325 shares during the last quarter. Wellington Management Group LLP raised its position in Humana by 38.8% during the 1st quarter. Wellington Management Group LLP now owns 8,775,376 shares of the insurance provider’s stock valued at $3,818,781,000 after purchasing an additional 2,453,565 shares during the last quarter. State Street Corp raised its position in Humana by 0.3% during the 4th quarter. State Street Corp now owns 5,726,024 shares of the insurance provider’s stock valued at $2,660,025,000 after purchasing an additional 15,994 shares during the last quarter. Finally, Capital Research Global Investors raised its position in Humana by 7.6% during the 1st quarter. Capital Research Global Investors now owns 4,164,456 shares of the insurance provider’s stock valued at $1,812,264,000 after purchasing an additional 292,456 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

About Humana

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

The Fly logo

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.